COPD and the Air We Breathe: Understanding a Major American Lung Disease

by | Sep 18, 2026

Breathing normally depends on thousands of small airways and millions of microscopic air sacs expanding, contracting, and exchanging gases with every breath.

Chronic obstructive pulmonary disease, or COPD, gradually damages that system.

COPD is not one single disease. The term primarily includes emphysema and chronic bronchitis, which frequently occur together. Both interfere with airflow and make it increasingly difficult to move air through the lungs.

Millions of Americans live with COPD, and many others may have the disease without knowing it.

For air-quality science, COPD is especially important because decades of exposure to inhaled material can help create the disease—and polluted air can continue affecting people after COPD has developed.

What Happens Inside a Lung With COPD?

Healthy airways are flexible tubes that allow air to move freely toward the alveoli, the tiny air sacs where oxygen enters the bloodstream and carbon dioxide leaves it.

COPD changes this structure.

In chronic bronchitis, airway walls become persistently inflamed and produce excessive mucus. The airway passage narrows, making airflow more difficult.

Emphysema damages the walls separating alveoli. Instead of millions of small elastic air spaces, portions of the lung develop larger, damaged spaces that exchange gases less efficiently.

The lungs can also lose some of their natural elasticity.

As a result, people with COPD may have particular difficulty pushing used air out of the lungs before taking the next breath.

Cigarette Smoke Remains the Leading U.S. Cause

Cigarette smoking remains the dominant cause of COPD in the United States.

Tobacco smoke repeatedly exposes airway tissue to particles, oxidants, and thousands of chemicals capable of causing inflammation and tissue damage.

The effects accumulate over years.

COPD is not exclusively a smokers’ disease, however.

CDC estimates indicate that as many as one-quarter of Americans with COPD have never smoked cigarettes.

Secondhand smoke, occupational exposure, outdoor pollution, childhood respiratory conditions, and abnormal lung development can all contribute.

A rare inherited condition called alpha-1 antitrypsin deficiency can also cause COPD by reducing the lungs’ protection against destructive enzymes released during inflammation.

Workplaces Can Contribute to Disease

Occupational exposure is an important part of the COPD story.

Miners, construction workers, agricultural workers, firefighters, manufacturing employees, and people working around combustion processes may repeatedly inhale dust, fumes, smoke, or chemical vapors.

Coal and mineral dust, welding fumes, silica, diesel exhaust, and other workplace contaminants have all been associated with chronic respiratory disease.

These exposures can become particularly important when combined with cigarette smoking.

COPD therefore illustrates how occupational and environmental air quality can produce health effects that may not become obvious until decades after exposure began.

Outdoor Air Pollution Can Add to the Burden

Fine particulate matter and other outdoor pollutants are also increasingly recognized as contributors to COPD.

PM2.5 can penetrate deeply into the respiratory system, while ozone and nitrogen dioxide can irritate and inflame airway tissues.

Long-term exposure may contribute to disease development and progression, while short-term pollution episodes can worsen symptoms or contribute to exacerbations—periods when COPD suddenly becomes more severe.

Wildfire smoke has become an increasingly important example because large smoke events can expose entire populations to elevated concentrations of fine particulate matter.

For someone whose lungs already have limited reserve, an additional environmental stressor can have much greater consequences than it would for healthy lungs.

COPD Is Usually Confirmed by Measuring Airflow

Symptoms alone cannot completely define COPD.

Persistent cough, mucus production, wheezing, shortness of breath, and declining exercise tolerance can occur with several respiratory and cardiovascular conditions.

One of the principal diagnostic tools is spirometry.

During spirometry, a person forcefully exhales into an instrument that measures how much air can be expelled and how quickly it leaves the lungs.

A commonly measured value called FEV1 represents the amount of air expelled during the first second.

Because COPD causes persistent airflow obstruction, these measurements help clinicians identify and characterize the disease.

Treatment Focuses on Managing a Chronic Disease

COPD currently has no cure that can restore all damaged lung tissue to its original condition.

Treatment instead focuses on improving airflow, controlling symptoms, preventing exacerbations, maintaining activity, and slowing further damage.

Bronchodilators relax muscles surrounding the airways, helping them remain more open.

Some patients receive combinations of long-acting bronchodilators, while inhaled corticosteroids or other anti-inflammatory medications are used for particular groups of patients.

Pulmonary rehabilitation combines supervised exercise, respiratory education, and other approaches intended to improve physical function and quality of life.

Supplemental oxygen is used for some people whose blood oxygen levels remain too low.

For selected patients with severe disease, lung-volume-reduction procedures, removal of large damaged air spaces, or lung transplantation may also be considered.

COPD Treatment Is Becoming More Specialized

The treatment landscape has recently expanded.

In 2024, the FDA approved ensifentrine, an inhaled medication that combines bronchodilator and anti-inflammatory activity through a different biological pathway from many traditional inhalers.

That same year, the biologic drug dupilumab was approved for certain adults with COPD characterized by elevated eosinophilic inflammation.

These developments reflect a broader change in respiratory medicine.

COPD was once treated largely according to how severely airflow was obstructed. Modern treatment increasingly considers exacerbation history, symptoms, inflammation, and differences in the underlying biology of individual patients.

The disease may eventually be viewed less as one condition and more as several overlapping forms of chronic lung injury.

COPD Remains a Major American Health Burden

In 2024, about 4.2 percent of U.S. adults reported having been diagnosed with COPD, emphysema, or chronic bronchitis.

The burden increases substantially with age.

Among Americans age 45 and older, 7 percent reported COPD in 2024. In nonmetropolitan areas, prevalence reached 10.6 percent, illustrating the particularly heavy burden in rural communities.

National COPD prevalence remained relatively stable between 2011 and 2022, while death rates declined over previous decades.

That is encouraging, but it does not mean the disease is disappearing.

America’s aging population means more people are entering the age groups where COPD becomes common. Former smokers remain at risk decades after quitting, and occupational exposures, wildfire smoke, and ambient air pollution remain relevant.

The Future May Be Better Treatment, Not Disappearance

Declining cigarette smoking should reduce future COPD associated with tobacco exposure.

At the same time, COPD is likely to remain a major chronic disease for decades because lung damage develops slowly and the population is aging.

The future of COPD will therefore involve two parallel efforts.

One is prevention: reducing tobacco smoke, workplace hazards, and harmful air pollution before irreversible lung damage develops.

The other is increasingly precise treatment for people who already have the disease.

COPD demonstrates one of the clearest long-term relationships between air and human health.

A single polluted day rarely creates chronic lung disease.

But the air inhaled over years—at home, at work, outdoors, and through personal habits—can eventually become part of the structure and function of the lungs themselves.

References